Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL2517552

N#Cc1cc(N/C(=N\O)c2nonc2NCc2ccc(CN3CCS(=O)(=O)CC3)cc2)ccc1F.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 5/20 0.38
GPR6 P46095 4/20 0.36
ALDH1A1 P00352 2/20 0.35
RAB9A P51151 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPT P10636 1/20 0.35
NPC1 O15118 1/20 0.34
AR P10275 1/20 0.34
KCNH2 Q12809 1/20 0.34
NAMPT P43490 1/20 0.34
CHRM4 P08173 2/20 0.34
CTNNB1 P35222 1/20 0.34
TCF7L2 Q9NQB0 1/20 0.34
CHRM2 P08172 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL2517559 1.00 IDO1 (0.38) IDO1GPR6ALDH1A1RAB9AKDM4E
SCHEMBL2517792 0.96 IDO1 (0.39) IDO1ALDH1A1RAB9AKDM4EMAPT
SCHEMBL2517793 0.96 IDO1 (0.39) IDO1ALDH1A1RAB9AKDM4EMAPT
SCHEMBL2517555 0.89 IDO1 (0.37) IDO1GPR6ALDH1A1RAB9AKDM4E
Trifluoroacetic Acid SCHEMBL2515038 0.89 IDO1 (0.46) IDO1GPR6KCNH2NAMPT
Trifluoroacetic Acid SCHEMBL2515043 0.89 IDO1 (0.46) IDO1GPR6KCNH2NAMPT
SCHEMBL14707358 0.89 IDO1 (0.39) IDO1ALDH1A1RAB9AKDM4EMAPT
SCHEMBL14237338 0.89 IDO1 (0.39) IDO1KCNH2NAMPT
SCHEMBL2517804 0.89 IDO1 (0.39) IDO1KCNH2NAMPT
SCHEMBL12053661 0.86 ALDH1A1 (0.36) IDO1GPR6ALDH1A1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192868-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2021-12-07 US disclosed
US-20190210985-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION 2019-07-11 US disclosed
US-10208002-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2019-02-19 US disclosed
US-20180030006-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION 2018-02-01 US disclosed
EP-3085697-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME Incyte Holdings Corporation (US) 2016-10-26 EP disclosed
EP-2559690-B1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE HOLDINGS CORP (US) 2016-03-30 EP disclosed
US-20140377292-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2014-12-25 US disclosed
US-8846726-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2014-09-30 US disclosed
US-20130123246-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2013-05-16 US disclosed
EP-2559690-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same Incyte Corporation (US) 2013-02-20 EP disclosed
US-8372870-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same for treating cancer INCYTE CORPORATION (US) 2013-02-12 US disclosed
EP-1879573-B1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORP (US) 2012-12-19 EP disclosed
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME INCYTE CORPORATION, A DELAWARE CORPORATION 2011-12-22 US disclosed
US-8034953-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION (US) 2011-10-11 US disclosed
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same INCYTE CORPORATION 2006-11-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10208002-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT IDO1 1/4885GPR6 1497/4885ALDH1A1 902/4885
US-20180030006-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885GPR6 1497/4885ALDH1A1 902/4885
US-11192868-B2 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT IDO1 1/4885GPR6 1497/4885ALDH1A1 902/4885
US-20060258719-A1 Modulators of indoleamine 2,3-dioxygenase and methods of using the same IDO1, IDO2, INMT IDO1 1/4885GPR6 1497/4885ALDH1A1 902/4885
US-20110311479-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885GPR6 1497/4885ALDH1A1 902/4885
US-20190210985-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885GPR6 1497/4885ALDH1A1 902/4885
US-20140377292-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885GPR6 1497/4885ALDH1A1 902/4885
US-20130123246-A1 MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE AND METHODS OF USING THE SAME IDO1, IDO2, INMT IDO1 1/4885GPR6 1497/4885ALDH1A1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.